TriangleHEALTH PROFESSIONAL · SOURCE READING
Surgery
Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 13, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs
Surgery may be added to medical therapy for selected patients with GISTs in an effort to delay or prevent recurrence, although the benefit of this therapeutic approach in patients with metastatic GISTs has yet to be proven in a randomized clinical trial.
Evidence (surgery):
A retrospective study involving 69 consecutive patients who underwent surgery for unresectable primary or metastatic GISTs while receiving kinase inhibitors reported the following:[48][Levels of evidence C2 and C1]
A retrospective study involving 69 consecutive patients who underwent surgery for unresectable primary or metastatic GISTs while receiving kinase inhibitors reported the following:[48][Levels of evidence C2 and C1]
Patients with stable disease or limited progression were found to have prolonged survival after debulking procedures. In this group of patients with GISTs, no evidence of disease was found after surgery in 78% of patients with stable disease, 25% of patients with limited progression, and 7% of patients with generalized progression.
A retrospective study involving 69 consecutive patients who underwent surgery for unresectable primary or metastatic GISTs while receiving kinase inhibitors reported the following:[48][Levels of evidence C2 and C1]
The 12-month PFS rate was 80% for patients with stable disease, 33% for patients with limited progression, and 0% for patients with generalized progression.
A retrospective study involving 69 consecutive patients who underwent surgery for unresectable primary or metastatic GISTs while receiving kinase inhibitors reported the following:[48][Levels of evidence C2 and C1]
The 12-month OS rate was 95% for patients with stable disease, 86% for patients with limited progression, and 0% for patients with generalized progression.
A retrospective study involving 69 consecutive patients who underwent surgery for unresectable primary or metastatic GISTs while receiving kinase inhibitors reported the following:[48][Levels of evidence C2 and C1]
The authors of this study concluded that surgery for patients with generalized progression should be limited to a palliative role.
Overall, the indications for surgery in the management of metastatic or recurrent GISTs include:[3]
Source links and citations
Stable disease (i.e., disease that is stable or shrinking on TKI therapy when gross resection is possible).
Limited disease progression (i.e., isolated tumor deposits that are progressing on TKI therapy after initial response [indicating delayed drug resistance], while other sites of disease remain stable).
Oncological emergencies including hemorrhage, perforation, obstruction, or abscess.
Stable disease and limited disease progression identify subsets of patients with advanced disease that are selected for relative disease stability. Therefore, the favorable outcomes that have been noted in case series may be principally the result of selection bias rather than true benefit from surgery.
The median time to the development of secondary resistance to imatinib has been about 2 years.[12] Therefore, it is suggested that surgery for metastatic or recurrent disease in patients receiving imatinib/sunitinib be performed before 2 years. Most experts would recommend considering surgery after 6 to 12 months of disease stability with TKI therapy.[3] Drug therapy may be continued after surgery.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice